Skip to main content

Advertisement

Table 2 Characteristics of patients and survival analysis (by the patterns of tumor enhancement)

From: Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer

Characteristic Homogeneous enhancement (n = 82) Heterogeneous enhancement (121) Peripheral enhancement (52) Statistics P
Age(years) 51.35 ± 8.51 52.24 ± 10.37 52.00 ± 9.53 0.210 0.811
Menopause     1.388 0.499
Postmenopausal 41 54 28   
Premenopausal 41 67 24   
Family history     1.095 0.579
No 76 111 50   
Yes 6 10 2   
Diameter 2.08 ± 0.91 2.31 ± 1.04 2.78 ± 1.28 7.028 0.001
Quadrant     12.629 0.125
Areolar 2 1 2   
Inner upper 13 29 3   
Inner lower 11 9 5   
Outer lower 13 22 8   
Outer upper 43 60 34   
Difference of MVD (Edge - Center) -0.42 ± 5.72 3.73 ± 4.67 17.02 ± 3.88 211.273 0.000
Grade of DMVD     179.854 0.000
Uniform distribution 77(93.9%) 110(90.9%) 0(0%)   
Uneven distribution 5(6.1%) 11(9.1%) 52(100%)   
Histological grade     2.021 0.732
I 22 31 10   
II 51 80 35   
III 9 10 7   
Cancer thrombosis     2.910 0.233
Negative 60 92 33   
Positive 22 29 19   
Nodal metastasis     1.588 0.452
Negative 25 61 22   
Positive 47 60 30   
Number of metastatic nodes 3.80 ± 6.88 2.51 ± 5.30 6.73 ± 10.17 6.540 0.002
Clinical stage     19.007 0.040
I 20(24.4%) 32(26.4%) 7(13.5%)   
IIA 25(30.5%) 37(30.6%) 14(26.9%)   
IIB 29(35.4%) 38(31.4%) 17(32.7%)   
IIIA 4(4.9%) 10(8.3%) 4(7.7%)   
IIIB 2(2.4%) 2(1.7%) 3(5.8%)   
IIIC 2(2.4%) 2(1.7%) 7(13.5%)   
IV 0(0%) 0(0%) 0(0%)   
ER     31.203 0.000
Negative 29(35.4%) 32(26.4%) 37(71.2%)   
Positive 53(64.6%) 89(73.6%) 15(28.8%)   
PgR     34.485 0.000
Negative 24(29.3%) 29(24.0%) 36(69.2%)   
Positive 58(70.7%) 92(76.0%) 16(30.8%)   
HER2     11.200 0.004
Negative 70(85.4%) 110(90.9%) 37(71.2%)   
Positive 12(14.6%) 11(9.1%) 15(28.8%)   
Ki67     14.736 0.001
Negative (<14%= 53(64.6%) 77(63.6%) 18(34.6%)   
Positive (>14%) 29(35.4%) 44(36.4%) 34(65.4%)   
P53 (%) 33.98 ± 32.59 30.35 ± 31.32 30.27 ± 33.83 0.357 0.700
Clinicopathological subtypes     59.901 0.000
Luminal A 40(48.8%) 71(58.7%) 8(15.4%)   
Luminal B (Ki67+) 18(22.0%) 29(24.0%) 5(9.6%)   
Luminal B (HER2+) 7(8.5%) 8(6.6%) 7(13.5%)   
HER2 overexpression 5(6.1%) 3(2.5%) 8(15.4%)   
TNBC 12(14.6%) 10(8.3%) 24(46.2%)   
Operation     4.885 0.087
Mastectomy 72 106 51   
Tumorectomy 10 15 1   
Chemotherapy program     14.344 0.279
Not performed 0 1 1   
CMF 1 1 0   
CAF or AC 23 42 7   
CEF or EC 19 27 16   
T or TC or TP 27 34 15   
TAC or A-T 12 16 13   
Radiotherapy     1.560 0.458
Not performed 40 69 26   
Performed 42 52 26   
Endocrine therapy     53.381 0.000
Not performed 17(20.7%) 13(10.7%) 32(61.5%)   
TAM 38(46.3%) 68(56.2%) 13(25.0%)   
LHRH 7(8.5%) 8(6.6%) 3(5.8%)   
AI 20(24.4%) 32(26.4%) 4(7.7%)   
Targeted therapy     2.329 0.312
Not performed 79 119 52   
Performed 3 2 0   
Overall survival 100% 95.9% 88.5% 11.876 0.018
Event 0 5 6   
Deaths 0 5 5   
Lost to follow-up 0 0 1   
Median survival time 54.0 54.0 42.0 8.525 0.014
Disease-free survival 100% 95.9% 65.4% 63.908 0.000
Event 0 5 18   
Local recurrence 0 0 1   
Contralateral breast cancer 0 0 4   
Lung metastasis 0 0 2   
Hepatic metastasis 0 0 5   
Brain metastasis 0 1 2   
Multi-organ 0 4 3   
Lost to follow-up 0 0 1   
Disease-free survival 54.0 54.0 29.5 45.952 0.000
Follow-up time     2.967 0.053
Median 21.0 25.0 21.0   
Range 12-56 12-59 12-44